Adebrelimab

Generic Name
Adebrelimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2247114-85-6
Unique Ingredient Identifier
1XBY50W1OX
Background

Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication

用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Phase 2
Not yet recruiting
Conditions
Solid Tumor
Interventions
Drug: Adebrelimab
Drug: Apatinib
Procedure: microwave ablation
First Posted Date
2024-08-05
Last Posted Date
2024-08-05
Lead Sponsor
Beidahuang Industry Group General Hospital
Target Recruit Count
60
Registration Number
NCT06537505

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Jiang Long
Target Recruit Count
40
Registration Number
NCT06531278
Locations
🇨🇳

Shanghai General Hospital, Shanghai, Shanghai, China

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

First Posted Date
2024-07-19
Last Posted Date
2024-07-19
Lead Sponsor
Fujian Medical University Union Hospital
Target Recruit Count
48
Registration Number
NCT06510660
Locations
🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

First Posted Date
2024-07-18
Last Posted Date
2024-07-18
Lead Sponsor
Harbin Medical University
Target Recruit Count
65
Registration Number
NCT06508229

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

First Posted Date
2024-07-17
Last Posted Date
2024-07-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
25
Registration Number
NCT06506292
Locations
🇨🇳

Tianjin Cancer Institute and Hospital, Tianjin, Tianjin, China

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

First Posted Date
2024-07-03
Last Posted Date
2024-08-02
Lead Sponsor
Jin Ying
Target Recruit Count
28
Registration Number
NCT06483282
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma

First Posted Date
2024-06-27
Last Posted Date
2024-06-27
Lead Sponsor
Zhangzhou Municipal Hospital
Target Recruit Count
40
Registration Number
NCT06478264

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

First Posted Date
2024-06-26
Last Posted Date
2024-08-09
Lead Sponsor
Fudan University
Target Recruit Count
87
Registration Number
NCT06475326
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
29
Registration Number
NCT06470633

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

First Posted Date
2024-06-24
Last Posted Date
2024-12-20
Lead Sponsor
Fudan University
Target Recruit Count
32
Registration Number
NCT06470672
Locations
🇨🇳

Fudan Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy